Ista, which sells Istalol for intraocular pressure and Bromday for issues associated with cataract extraction, earlier this year rebuffed a $327 million hostile bid by Valeant Pharmaceuticals International Inc. (VRX) Bausch’s offer is 134 percent more than Ista’s share price on Dec. 15, the day before Valeant’s bid became public.
The deal is expected to close in the second quarter, according to a statement yesterday from Ista and Rochester, New York-based Bausch, which is owned by Warburg Pincus LLC. Bausch said the deal is financed with cash and a $350 million loan.
Valeant, Canada’s largest drugmaker, dropped its offer of $7.50 a share on Jan. 30, citing lack of progress making a deal. Ista had called Valeant’s share “grossly inadequate.”
To contact the editor responsible for this story: Reg Gale at email@example.com